Cost, Pricing, and Reimbursement Challenges of ADC Therapies
As ADCs become more prevalent in oncology, concerns around their cost and reimbursement are mounting. The Antibody Drug Conjugate market includes some of the most expensive cancer therapies, often priced at hundreds of thousands of dollars per course.
The high cost is driven by complex manufacturing, specialized payloads, and stringent regulatory requirements. Additionally, many ADCs are indicated for rare cancers, limiting economies of scale. These factors contribute to significant pricing pressures on healthcare systems, payers, and patients.
Reimbursement is not guaranteed, especially in markets with centralized healthcare budgets or lack of private insurance coverage. Health Technology Assessment (HTA) agencies like NICE in the UK require ADCs to demonstrate clear cost-effectiveness compared to existing treatments.
To address these concerns, some developers are adopting value-based pricing models, where payment is linked to treatment outcomes. Others are negotiating risk-sharing agreements with payers or providing patient access programs.
As biosimilar development for ADCs becomes feasible, competition may eventually bring down prices. Policymakers are also exploring reimbursement reforms to ensure innovation does not come at the expense of accessibility.